Q3 2025 Precigen Inc Earnings Call Transcript

Nov 13, 2025 / 09:30 PM GMT

Release Date Price: $3.86 (-3.98%)

Transcript 10-Q8-K

Key Points

Positve

Precigen Inc (PGEN) received full FDA approval for Papsius, marking a significant milestone in the treatment of recurrent respiratory papillomatosis (RRP).
Papsius demonstrated a 51% complete response rate, with 86% of patients experiencing a reduction in surgical burden.
The company has successfully launched Papsius in the U.S., with 90% of target institutions engaged and over 100 patients registered for treatment.
Papsius has a favorable safety profile and is easy to administer, requiring only a subcutaneous injection.
Precigen Inc (PGEN) has submitted a marketing authorization application with the EMA, indicating plans for geographic expansion.

Negative

The company is not yet providing specific revenue guidance, making it difficult to assess financial projections.
There are reimbursement hurdles typical for new therapies, which could impact the speed of patient uptake.
Increased SG&A costs due to commercialization efforts have contributed to a higher net loss for the quarter.
The company faces competition in the RRP treatment space, which could impact market share.
Precigen Inc (PGEN) has a complex financial structure, including recent conversions of preferred shares, which may affect investor perception.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PGEN.OQ - Precigen Inc
Q3 2025 Precigen Inc Earnings Call
Nov 13, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon ladies and gentlemen, and welcome to the Press 3rd quarter 2025 financial results and business updates conference call.

At this time, all lines are in listen-only mode.

Following the presentation, we will conduct a question-and-answer session.

If at any time during this call you require immediate assistance, please press 0 for the operator.

This call is being recorded on Thursday, November 13, 2025.

I would now like to turn the conference over to Steve Harassim.

Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.